LSD Microdosing Study Finds ‘No Residual Effects’ on Mood or Cognition
Another study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
Psychedelic Spotlight News
Interview with Dr. Erica Zelfand
This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
4 Signs the Psychedelics Movement Is Unstoppable
With no strong resistance manifesting to oppose the psychedelic renaissance, it appears these drugs have re-emerged from underground for a permanent place in our culture.
Irwin Naturals’ Mission to Make Ketamine Therapy Affordable for the Masses
The revered wellness brand wields proven business savvy to innovate, disrupt and equalize through its ketamine clinics.
How Long Until Psychedelic Stocks Payoff?
Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing in psychedelic stocks.
‘Altered States’: How One of Horror’s Most Psychedelic Films Altered My Life
Filmmaker Matthew Dunehoo, the director of our “Spotlight in Focus” series, reflects on a 1980 sci-fi horror movie that every psychonaut should see, and can probably relate to.
Psychedelic Business Spotlight – February 18
This week in psychedelic business news: Nova Mentis makes progress on autism; atai donates to MAPS; Cathie Wood eyes more psychedelic stocks.
When Will Psilocybin Be Available in Oregon and What’s the Hold-Up?
The Oregon Health Authority has until December 31, 2022, to finalize the framework, paving the way for licensure in early 2023.
Cybin Partners with The Chopra Foundation to Bring Awareness to the Benefits of Psychedelic-Based Therapies
“The need for new and more effective treatments across the mental health spectrum is more urgent today than ever,” says Dr. Deepak Chopra.
Interview with Joe Moore, Founder & CEO of Psychedelics Today
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.
End of content
End of content